Open Access

REVIEW

LAZAR S. POPOVIC^1,2,*, GORANA MATOVINA-BRKO¹, MAJA POPOVIC^1,2, KEVIN PUNIE³, ANA CVETANOVIC^4,5, MATTEO LAMBERTINI^6,7
Oncology Research, Vol.31, No.3, pp. 221-238, 2023, DOI:10.32604/or.2023.028525
Abstract Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%–15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of TNBC as follows: two basal-like… More >

Graphic Abstract

View

3329

Download

1152

Like

1

Open Access

ARTICLE

YU LU¹, TSUTOMU MIYAMOTO^1,*, HODAKA TAKEUCHI¹, FUMI TSUNODA¹, NAOKI TANAKA^2,3,4, TANRI SHIOZAWA¹
Oncology Research, Vol.31, No.3, pp. 239-253, 2023, DOI:10.32604/or.2023.026067
Abstract Endometrial carcinoma (EMC) is associated with obesity; however, the underlying mechanisms have not yet been elucidated. Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor that is involved in lipid, glucose, and energy metabolism. PPARα reportedly functions as a tumor suppressor through its effects on lipid metabolism; however, the involvement of PPARα in the development of EMC remains unclear. The present study demonstrated that the immunohistochemical expression of nuclear PPARα was lower in EMC than in normal endometrial tissues, suggesting the tumor suppressive nature of PPARα. A treatment with the PPARα activator, irbesartan, inhibited the EMC cell lines, Ishikawa and… More >

View

902

Download

480

Like

1

Open Access

REVIEW

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*
Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942
Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients experience great side effects after… More >

Graphic Abstract

View

2348

Download

591

Like

1

Open Access

VIEWPOINT

ALESSANDRO GOZZETTI^*, MONICA BOCCHIA
Oncology Research, Vol.31, No.3, pp. 271-274, 2023, DOI:10.32604/or.2023.028668
Abstract Novel drug availability has increased the depth of response and revolutionised the outcomes of multiple myeloma patients. Minimal residual disease evaluation is a surrogate for progression-free survival and overall survival and has become widely used not-only in clinical trials but also in daily patient management. Bone marrow aspiration is the gold standard for response evaluation, but due to the patchy nature of myeloma, false negatives are possible. Liquid biopsy and blood-based minimal residual disease evaluation consider circulating plasma cells, mass spectrometry or circulating tumour DNA. This approach is less invasive, can provide a more comprehensive picture of the disease and… More >

View

1095

Download

609

Like

1

Open Access

ARTICLE

LU LIU^1,2, BIN XIE^1,2, WEI ZHU^1,2, QIUYAN HE^1,2, JIANHUA ZHOU^1,2, SHUANG LIU³, YONGGUANG TAO⁴, DESHENG XIAO^1,2,*
Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227
（This article belongs to the Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous cell cancer (LUSC) patients and… More >

View

918

Download

472

Like

1

Open Access

ARTICLE

QIOU GU, TIAN ZHAN, XIAO GUAN, CHUILIN LAI, NA LU, GUOGUANG WANG, LEI XU, XIANG GAO, JIANPING ZHANG^*
Oncology Research, Vol.31, No.3, pp. 287-297, 2023, DOI:10.32604/or.2023.028124
（This article belongs to the Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
Abstract Background: Gastric cancer (GC) is a malignancy with the worst prognosis that seriously threatens human health, especially in East Asia. Apolipoprotein C1 (apoc1) belongs to the apolipoprotein family. In addition, apoc1 has been associated with various tumors. However, its role in GC remains unclear. Methods: Firstly, we quantified its expression in GC and adjacent tumor tissues, using The Cancer Genome Atlas (TCGA). Next, we assessed cell invasion and migration abilities. Finally, we revealed the role of apoc1 in the tumor microenvironment (TME), immune cell infiltration and drug sensitivity. Results: Firstly, in TCGA database, it has been shown that elevated expression… More >

View

1375

Download

551

Like

1

Open Access

ARTICLE

OZAN CEM GULER^1,*, EZGI OYMAK², GOZDE YAZICI³, OZLEM OZKAYA AKAGUNDUZ⁴, OGUZ CETINAYAK⁵, PETEK ERPOLAT⁶, ATIL AKSOY⁷, MURSEL DUZOVA⁸, BERNA AKKUS YILDIRIM⁹, MERAL KURT¹⁰, EMINE CANYILMAZ¹¹, GULER YAVAS¹², SERAP AKYUREK¹³, DIDEM COLPAN OKSUZ¹⁴, ESRA KAYTAN SAGLAM¹⁵, OMUR KARAKOYUN CELIK¹⁶, ENIS OZYAR¹⁷, MUSTAFA CENGIZ³, CEM ONAL^1,2,12
Oncology Research, Vol.31, No.3, pp. 299-306, 2023, DOI:10.32604/or.2023.028840
Abstract The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received… More >

View

639

Download

457

Like

1

Open Access

ARTICLE

NING AN^1,#, HEQING PENG^2,#, MIN HOU³, DUOFENG SU², LIU WANG⁴, XIAOGANG SHEN^5,*, MING ZHANG^1,*
Oncology Research, Vol.31, No.3, pp. 307-316, 2023, DOI:10.32604/or.2023.028564
Abstract Zinc-finger proteins play different roles in cancer; however, the function of zinc-finger protein ZNF575 in cancer remains unclear. In the present study, we aimed to determine the function and expression of ZNF575 in colorectal cancer. Proliferation assay, colony formation assay, and tumor model in mice were used to investigate the function of ZNF575 after ectopic expression of ZNF575 in colorectal cancer (CRC) cells. RNA sequencing, ChIP, and luciferase assays were used to investigate the mechanism behind ZNF575 regulation of CRC cell growth. The expression of ZNF575 was determined by IHC staining in 150 pairs of malignant CRC tissues, followed by… More >

Graphic Abstract

View

2291

Download

515

Like

1

Open Access

ARTICLE

YUSEN ZHANG^1,2,3, LIPING LIU^1,2,3, BIWEI LUO^1,2,3, HONGGUI TANG^1,2,3, XIAOFANG YU^1,2,3, SHIYUN BAO^1,2,3,*
Oncology Research, Vol.31, No.3, pp. 317-331, 2023, DOI:10.32604/or.2023.028418
Abstract Background: Cholangiocarcinoma (CCA) represents the epithelial cell cancer with high aggressiveness whose five-year survival rate is poor with standard treatment. Calcyclin-binding protein (CACYBP) shows aberrant expression within several malignant tumors, but the role of CACYBP in CCA remains unknown. Methods: Immunohistochemical (IHC) analysis was used to identify CACYBP overexpression in clinical samples of CCA patients. Moreover, its correlation with clinical outcome was revealed. Furthermore, CACYBP’s effect on CCA cell growth and invasion was investigated in vitro and in vivo using loss-of-function experiments. Results: CACYBP showed up-regulation in CCA, which predicts the dismal prognostic outcome. CACYBP had an important effect on… More >

View

1162

Download

470

Like

1

Open Access

ARTICLE

YAPING GAN^1,2,#, TING LIU^3,#, WEIFENG FENG^1,#, LIANG WANG⁴, LI LI⁵, YINGXIA NING^1,*
Oncology Research, Vol.31, No.3, pp. 333-343, 2023, DOI:10.32604/or.2023.028694
（This article belongs to the Special Issue: Role of Reactive Oxygen Species and DNA Damage in Tumor Immunological Responses)
Abstract Various therapeutic strategies have been developed to overcome ovarian cancer. However, the prognoses resulting from these strategies are still unclear. In the present work, we screened 54 small molecule compounds approved by the FDA to identify novel agents that could inhibit the viability of human epithelial ovarian cancer cells. Among these, we identified disulfiram (DSF), an old alcohol-abuse drug, as a potential inducer of cell death in ovarian cancer. Mechanistically, DSF treatment significantly reduced the expression of the anti-apoptosis marker B-cell lymphoma/leukemia-2 (Bcl-2) and increase the expression of the apoptotic molecules Bcl2 associated X (Bax) and cleaved caspase-3 to promote… More >

View

928

Download

527

Like

1

Open Access

ARTICLE

TAO LI^#, XIN FU^#, JIE WANG, WEI SHANG, XIAOTONG WANG, LINYUN ZHANG, JUN LI^*
Oncology Research, Vol.31, No.3, pp. 345-359, 2023, DOI:10.32604/or.2023.028724
Abstract Temozolomide (TMZ) resistance is a major obstacle in glioma treatment. Nuclear protein-1 (NUPR1) is a regulator of glioma progression. This study investigated the mechanism of NUPR1 in TMZ resistance in hypoxia-treated glioma cells and its mechanism in modulating autophagy. We treated TMZ-resistant cells U251-TMZ and T98G-TMZ to normoxia or hypoxia and silenced NUPR1 in hypoxia-treated U251-TMZ and T98G-TMZ cells to assess cell viability, proliferation, apoptosis, LC3-II/LC3-I and p62 expressions, and autophagic flux under different concentrations of TMZ. We found that hypoxia upregulated NUPR1 expression and autophagy while NUPR1 silencing suppressed hypoxia-induced TMZ resistance and autophagy in glioma cells. We also… More >

Graphic Abstract

View

2794

Download

723

Like

1

Open Access

ARTICLE

FRANCISCO RAÚL BORZONE^1,*, MARÍA BELÉN GIORELLO¹, LEANDRO MARCELO MARTINEZ², MARÍA CECILIA SANMARTIN^1,3, LEONARDO FELDMAN⁴, FEDERICO DIMASE⁵, EMILIO BATAGELJ⁶, GUSTAVO YANNARELLI³, NORMA ALEJANDRA CHASSEING^1,*
Oncology Research, Vol.31, No.3, pp. 361-374, 2023, DOI:10.32604/or.2023.028104
Abstract Breast cancer is the predominant form of carcinoma among women worldwide, with 70% of advanced patients developing bone metastases, with a high mortality rate. In this sense, the bone marrow (BM) mesenchymal stem/stromal cells (MSCs) are critical for BM/bone homeostasis, and failures in their functionality, transform the BM into a pre-metastatic niche (PMN). We previously found that BM-MSCs from advanced breast cancer patients (BCPs, infiltrative ductal carcinoma, stage III-B) have an abnormal profile. This work aims to study some of the metabolic and molecular mechanisms underlying MSCs shift from a normal to an abnormal profile in this group of patients.… More >

View

904

Download

518

Like

1

Open Access

ARTICLE

SHUIZHONG CEN^1,#, XIAOJIE PENG^2,#, JIANWEN DENG^3,#, HAIYUN JIN⁴, ZHINAN DENG⁵, XIAOHUA LIN³, DI ZHU³, MING JIN⁶, YANWEN ZHU³, PUSHENG ZHANG³, YUNFENG LUO³, HONGYAN HUANG^3,*
Oncology Research, Vol.31, No.3, pp. 375-388, 2023, DOI:10.32604/or.2023.028256
Abstract Triple-negative breast cancer (TNBC) is characterized by fast growth, high metastasis, high invasion, and a lack of therapeutic targets. Mitosis and metastasis of TNBC cells are two important biological behaviors in TNBC malignant progression. It is well known that the long noncoding RNA AFAP1-AS1 plays a crucial role in various tumors, but whether AFAP1-AS1 is involved in the mitosis of TNBC cells remains unknown. In this study, we investigated the functional mechanism of AFAP1-AS1 in targeting Polo-like Kinase 1 (PLK1) activation and participating in mitosis of TNBC cells. We detected the expression of AFAP1-AS1 in the TNBC patient cohort and… More >

Graphic Abstract

View

2448

Download

611

Like

1

Open Access

ARTICLE

JIAHENG XIE^1,#, MENGMENG OU^1,#, PAN YU^1,#, DAN WU^2,#, QIKAI TANG³, YUAN CAO⁴, JING HANG⁵, LU YIN¹, TINGHONG XIANG¹, MING WANG^1,*, JINGPING SHI^1,*
Oncology Research, Vol.31, No.3, pp. 389-403, 2023, DOI:10.32604/or.2023.029274
Abstract Purpose: To screen potential tumor antigens for melanoma vaccine development and identify different immune subtypes. Methods: Transcriptional data (HTSEQ-FPKM) and clinical information of a 472 Melanoma cohort GDC TCGA Melanoma (SKCM) were downloaded from the UCSC XENA website (). Subsequently, transcriptome data and clinical information of 210 melanoma cohort GSE65904 were downloaded from Gene Expression Omnibus (GEO), a large global public database. All the transcriptome expression data matrices were log2 transformed for subsequent analysis. GEPIA, TIMER, and IMMPORT databases are also used for analysis. Cell function experiments were performed to validate the role of the IDO1 gene in melanoma cell… More >

View

997

Download

490

Like

1